Recently, 11 societies have collaborated and endorsed a set of guidelines designed to improve patient outcome in sepsis (3) . In addition, drotrecogin alfa (activated) (DrotAA), a recombinant form of human activated protein C, has been approved in Ͼ50 countries for the treatment of severe sepsis patients at high risk of death or with multiple organ dysfunctions.
Approval of DrotAA for treatment of severe sepsis was based on results of the PROWESS trial (4) . PROWESS was a double blind, placebo-controlled trial that enrolled 1,690 patients, randomly assigned to receive DrotAA (n ϭ 850) or placebo (n ϭ 840), in addition to standard care. At a predefined interim analysis, an independent data monitoring board recommended that the trial stop early due to the demonstrated efficacy. As the only compound approved for reduction of mortality from severe sepsis, subsequent trials designed to better under-stand severe sepsis and the mechanism of action of DrotAA became an ethical conundrum, particularly with regard to the use of a control group. To provide important supplementary safety and efficacy evaluation, ENHANCE was the vehicle chosen to provide this information and was designed as a global, open-label, single arm trial.
Although single-arm trials have the inherent problem of being unblinded and having no placebo control, they can provide important supplementary safety data as well as potential confirmatory efficacy data by reproducing an efficacy outcome similar to a phase III trial, in this case PROWESS. In addition, open-label trials can potentially provide a different aspect as to how a compound may be used in everyday clinical practice because they are predominantly performed in a wider sampling of hospitals outside the typical academic institution setting of a phase III trial (5) .
The underlying premise for the EN-HANCE clinical trial was that DrotAA would have similar efficacy and safety in a setting more like normal clinical practice than that observed in the PROWESS clinical trial. The primary objectives of the ENHANCE trial were to provide additional safety and efficacy information concerning the use of DrotAA among patients with severe sepsis.
METHODS

Patients
ENHANCE was a multiple-country, singlearm, open-label study of DrotAA in adult and pediatric patients with severe sepsis (only adult data, patients Ն18 yrs, are presented and discussed). It was conducted in 25 countries at 361 investigative sites. The study was conducted in accordance with applicable laws and regulations, good clinical practices, and ethical principles that have their origin in the Declaration of Helsinki. Standardized guidelines of good clinical practice, as stated in the International Council on Harmonization, were followed in design of the trial. All institutional review boards provided approvals. Appropriate informed consent was obtained from all patients or their legal representative. EN-HANCE was begun after completion of PROW-ESS (June 2000) . Enrollment began in March 2001 and ended in December 2002, and day 28 follow-up was completed in January 2003. Since ENHANCE was initiated before regulatory approval and included all patients with severe sepsis, not just those at high risk or with multiple organ dysfunction as subsequently indicated by regulatory authorities, ENHANCE was a phase IIIB trial. Data were source verified, and data lock occurred in April 2003. The clinical coordinating center (Vanderbilt Coordinating Center, Nashville, TN) was available 24 hrs a day throughout the study to answer investigators' questions regarding patient eligibility and safety and the reporting of serious adverse events.
ENHANCE inclusion/exclusion criteria were essentially the same as used in PROW-ESS (4) and were a modification of severe sepsis criteria that have been described in detail previously (6, 7) . Briefly, three inclusion criteria were required: a) the presence of known or suspected infection; b) at least three of the four criteria defining systemic inflammatory response syndrome (SIRS); and c) one or more sepsis-induced organ dysfunctions (cardiovascular, respiratory, renal, hematologic, metabolic acidosis). A detailed summary of exclusion criteria can be found elsewhere (4) but they included pregnancy or breastfeeding, body weight Ͼ135 kg, platelet count Ͻ30,000/mm 3 , sepsis-induced organ dysfunction of Ͼ48 hrs, conditions that increase the risk of clinically important bleeding, and known hypo-or hypercoagulable conditions.
In PROWESS (4), patients had to meet all entry criteria within a 24-hr time period (Window 1, Fig. 1 ). From that point, an additional 24 hrs were allowed to consent and randomize the patient to treatment and initiate study drug infusion (Window 2, Fig. 1 ). If organ dysfunction was the first documented inclusion criteria, the maximum duration of organ dysfunction that could occur before the start of DrotAA infusion was 48 hrs.
In ENHANCE, a single-window approach was used (Fig. 1 ). Patients were included if they met the entry criteria, they consented, and infusion begun within 48 hrs of their first organ dysfunction. As in PROWESS, the maximum duration of organ dysfunction before treatment with DrotAA could be no longer than 48 hrs. This single window design was thought to better reflect the likely use of DrotAA in normal clinical practice.
Interventions
ENHANCE was an open-label trial with all patients receiving DrotAA in addition to standard care. As in the PROWESS DrotAA arm (4), all ENHANCE patients received DrotAA (Xigris, Eli Lilly and Co., Indianapolis, IN) at a dosage of 24 g/kg/hr for 96 hrs.
Trial Measurements
The primary measurement was 28-day allcause mortality. Serious bleeding events during infusion and for the 28-day period were Figure 1 . ENHANCE protocol design. In both studies, the maximum duration of sepsis-induced organ dysfunction before treatment with drotrecogin alfa (activated) (DrotAA) could be no longer than 48 hrs. PROWESS had a two-window design. Patients had to meet inclusion criteria within a 24-hr period and then receive DrotAA in Յ24 hrs from the point in time when all criteria were met. ENHANCE had a one-window design. Patients could meet inclusion criteria any time within 48 hrs from first organ dysfunction, as long as they received DrotAA within the 48-hr window. also recorded. Before infusion, baseline characteristics including demographics, information on preexisting conditions, organ function, markers of disease severity, infection, and other laboratory tests were assessed. Blood samples were taken just before infusion and at the end of infusion. A central laboratory (Covance Central Lab Services, Indianapolis, IN) performed protein C measurements using established techniques. Briefly, protein C levels were determined by a clot end-point technique using an STA coagulation analyzer and STA-Clot kits (Diagnostica-Stago, AsnieresSur-Seine, France).
Definitions
On Vasopressors. A cardiovascular Sequential Organ Failure Assessment (SOFA) score of 3 or 4 (dopamine Ͼ5 g/kg/min or any dose of epinephrine, norepinephrine, or phenylephrine) was used.
Surgery. Surgery was defined as any surgery within 30 days and/or Acute Physiology and Chronic Health Evaluation (APACHE) II surgical status.
Total SOFA. The total SOFA score was calculated as the sum of the six individual baseline SOFA scores (respiratory, coagulation, liver, cardiovascular, central nervous system, and renal) (8) .
Bleeding Events. Serious bleeding events were defined as events associated with bleeding that met the criteria for a serious adverse event (discussed subsequently) or were associated with any of the following outcomes or treatment: death, intracranial hemorrhage (ICH), and treatment by transfusion of packed red blood cells Ն3 units/day for 2 consecutive days. It should be noted there were seven bleeding events (five during infusion and two postinfusion) where transfusion of packed red blood cells was not associated with clear evidence of a bleeding event. The "during infusion" category was defined as the actual infusion period plus one calendar day postinfusion. This additional calendar day ensured that DrotAA would be cleared from the circulation. The "postinfusion" period was defined as the period from the end of the infusion period until the 28-day time point. Two Eli Lilly physicians independently adjudicated procedure-related bleeding.
Serious adverse events were defined as events that resulted in one of the following outcomes or were considered significant for any other reason by the investigator: prolonged inpatient hospitalization or rehospitalization, a life-threatening experience (i.e., the patient was in immediate risk of dying), severe or permanent disability, cancer, congenital anomaly, death, and events that met the previously described criteria for a serious bleeding event. Clinical outcomes of severe sepsis were exempt from serious adverse event reporting, unless the investigator deemed them related to the use of DrotAA.
Time From First Organ Dysfunction to start of DrotAA Infusion. This prospectively defined analysis was categorized as 0 -24 hrs (early) or Ͼ24 hrs (late) from the first documented sepsis-induced organ dysfunction to treatment with DrotAA (i.e., time-to-treatment populations).
Statistical Analysis
Results across the ENHANCE and PROW-ESS studies are presented in the context of observational comparison, with no statistical assessment. Twenty-eight day all-cause mortality rates with exact 95% confidence intervals (CI) are reported. Cumulative 28-day mortality and Kaplan-Meier 28-day survival curves are also displayed. PROWESS and ENHANCE mortality rates by key subgroups are presented observationally, with no statistical assessment. Serious bleeding rates (with exact 95% CIs) and other safety data are also presented in the context of observational comparison.
Assessments of statistical significance were performed within the ENHANCE study. As prospectively defined in the study protocol, 28-day all-cause mortality (with exact 95% CIs) by time from first documented sepsisinduced organ dysfunction to start of treatment (i.e., 0 -24 hrs, Ͼ24 hrs) was analyzed via Pearson's chi-square test. To account for potential imbalances in the time-to-treat groups, stratified analyses by individual subgroups were also performed based on Cochran-Mantel-Haenszel tests. As recommended by the CONSORT guidelines (9), the BreslowDay test (10) was used to assess time to treatment by subgroup interactions. Patient characteristics by time to treatment class were compared via Wilcoxon's rank-sum (continuous) and Pearson's chi-square (categorical) tests.
While simultaneously adjusting for multiple covariates, the association between mortality and timing of treatment class was assessed via multivariate logistic regression. Inferences were based on odds ratio estimates (ratio of odds of dying when treated early vs. treated late) and corresponding 95% Wald confidence intervals. The p values for assessing the significance of the time to treatment covariate were based on Wald's chi-square tests.
In all cases, p values were two-sided. Statistical significance was inferred if p Ͻ .05. All analyses were performed using SAS software, version 8.2 for Windows (SAS Institute, Cary, NC).
Missing Data. As prospectively defined in the protocol, patients with unavailable 28-day survival status were excluded from all mortality analyses. In addition, for each analysis, if any specific baseline data for a patient were missing, these data were excluded from any related calculations.
RESULTS
A total of 2,434 adult patients were entered into the study. Of these, 2,378 (97.7%) received DrotAA. Figure 2 shows the patient disposition in ENHANCE. Three patients did not complete the protocol and had no 28-day survival status information.
ENHANCE Baseline Characteristics With Respect to PROWESS
Selected baseline characteristics of ENHANCE patients are displayed in Table  1 . The most common site of infection was the lung (46.8%). The infecting organism was identified in 62.8% of patients, with pure Gram-positive infections being the most prevalent (26.6%). At baseline, a majority of ENHANCE patients were on vasopressors (73.7%) and treated with mechanical ventilation (82.0%). More than 40% of patients had severe protein C deficiency (Յ40%), and close to 90% had protein C levels below the lower limit of normal (Յ80%). The mean number of organ dysfunctions was 2.7, and the vast majority of patients (84.4%) had two or more organ dysfunctions. Table 1 also lists the same baseline characteristics for placebo-and DrotAAtreated patients enrolled in PROWESS (4), for observational comparison. EN- Figure 2 . ENHANCE patient disposition. Patients were assessed, they were enrolled if inclusion criteria were met, and drotrecogin alfa (activated) (DrotAA) was administered for 96 hrs at a dose of 24 g/kg/hr. Fifty-six patients did not receive DrotAA because they did not meet entry criteria. Of the treated patients, two were lost to follow-up and one withdrew consent.
HANCE patients were more likely to be Caucasian and have undergone surgery. Blood and intra-abdominal infections were more common in ENHANCE than in PROWESS patients, whereas lung and urinary tract infections were less common. Although APACHE II scores were lower in ENHANCE than PROWESS, all other measures of disease severity were higher (i.e., more patients on vasopressors, mechanically ventilated, with multiple organ dysfunctions, and higher total SOFA score). Severe protein C deficiency (Յ40% of normal) was similar in both studies.
ENHANCE Survival With Respect to PROWESS
The 28-day all-cause mortality rate for ENHANCE patients was 25.3% (23.5-27.1, 95% CI), which was very close to the rate observed in PROWESS patients (24.7%) (4). In addition, as shown in the Kaplan-Meier curves of Figure 3 , the pattern of survival was essentially identical for ENHANCE patients and PROWESS DrotAA-treated patients. Both curves were higher than the PROWESS placebotreated patients' curve.
Cumulative 28-day all-cause mortality for the ENHANCE trial is displayed in Figure 4 . For the first 5-6 months of the trial, there was considerable variability in the observed mortality rate. After approximately 6 months ‫005ف(‬ patients), the variability stabilized at the 25.3% level of mortality observed at the end of the trial. Table 2 presents the 28-day all-cause mortality rates for both studies by age and multiple measures of disease severity. Observational comparison suggested similar results in the DrotAA-treated populations of ENHANCE and PROWESS. In general, mortality rates by disease severity of DrotAA-treated patients in PROW-ESS and ENHANCE were consistent and both were lower than PROWESS placebo patients. Exceptions to this were observed in mortality by the APACHE II measure of disease severity (APACHE II scores Ͻ25 and APACHE II first, second, and third quartiles), where placebo patient mortality was less than or equal to DrotAA-treated patients. These exceptions contrasted with all other measures (i.e., number of organ dysfunctions, total SOFA score, patients on vasopressors, and mechanical ventilation), where pla- Figure 4 . ENHANCE cumulative mortality rate over time. Twenty-eight day mortality rate and patient enrollment were evaluated over the course of the trial in a cumulative fashion. Cumulative mortality over time is displayed on the left-hand y-axis. Cumulative patient number over time is displayed on the right-hand y-axis. Mortality stabilized after 6 months ‫005ف(‬ patients). The portion of the curve containing the first five patients has been removed to keep the curve on scale. However, their data were used in all calculations. The ENHANCE Kaplan-Meier Survival curve was overlaid on the PROWESS curve for direct comparison. The PROWESS and ENHANCE drotrecogin alfa (activated) (DrotAA)-treated curves were essentially identical and both were higher than the placebo survival curve.
cebo-treated patient mortality was greater than DrotAA-treated patients.
ENHANCE Safety Profile With Respect to PROWESS
As in PROWESS, bleeding was for the most common adverse event related to DrotAA treatment in ENHANCE. Displayed in the right-hand column of Table  3 is the proportion of patients enrolled in ENHANCE who experienced one or more bleeding events reported as a serious adverse event during the infusion period, the postinfusion period, and the entire 28-day study period. Corresponding data for the placebo-and DrotAA-treated populations from PROWESS (4) are also included for comparison.
During the infusion period, 3.6% of ENHANCE patients experienced a serious bleeding event compared with 2.4% and 1.0% in DrotAA-and placebo-treated patients, respectively, from PROWESS (4) . Approximately 50% of serious bleeding events that occurred during the infusion period were characterized as being procedure-related. During the postinfusion period, 3.2% of patients experienced a serious bleeding event compared with 1.2% and 1.1% in DrotAA-and placebotreated patients, respectively, from PROWESS.
Fifteen ENHANCE patients (0.6%) experienced an ICH event during infusion, of which five (0.2%) were fatal (Table 3) . Of these patients, two had hypertensive bleeding complications after the end of infusion; three were associated with severe shock and multiple organ dysfunction (all fatal); four experienced a large, nonfatal ICH; and six experienced a small, nonfatal hemorrhage (hemorrhage in one patient was investigator-defined but not confirmed on computed tomography scan and four of the remaining five patients had a diagnosis of meningitis). During the postinfusion period, 20 patients (0.8%) experienced an ICH event, and seven (0.3%) were fatal.
ENHANCE Time to Treatment Effect
Baseline characteristics of the time to treatment populations from ENHANCE are displayed in Table 4 . In PROWESS, the vast majority of patients (89%) were treated in Յ24 hrs. The PROWESS mean time from first organ dysfunction to start of DrotAA infusion was 17.4 hrs (Ϯ11.1 SD). In ENHANCE, the mean time from first organ dysfunction to start of DrotAA infusion was 26.1 hrs (Ϯ13.1 SD), and the proportion of patients who received DrotAA in 0 -24 hrs or Ͼ24 hrs was comparable (47.5% and 52.5%, respectively). Differences were observed when baseline characteristics of the time to treatment populations were analyzed and compared. Patients treated later (Ͼ24 hrs) were more likely to be male and older and to have had recent surgery. Although patients treated later tended to have a lower APACHE II score (21.6 vs. 22.5, driven by differences in Acute Physiology Score (APS) score, 18.1 vs. 19.2), other measures suggested their disease severity was worse, including the need for vasopressors and mechanical ventilation, the number of organ dysfunctions, and total SOFA score.
Patients treated earlier had significantly lower (p ϭ .01) 28-day all-cause mortality (22.9%, 20.5-25.5, 95% CI) than those treated later (27.4%, 24.9 -29.9, 95% CI). The corresponding time to treatment survival curves (0 -24 and Ͼ24 hrs) are shown in Figure 5 . The two curves began to diverge from each other around 14 days from the beginning of infusion. For all measures of disease severity, except mechanical ventilation and number of organ dysfunctions, mortality by disease severity was significantly greater in patients treated later, compared with earlier treatment, and was numerically higher in all subgroups except those having four organ dysfunctions (Table 5 ). No differences in the serious bleeding rates of the time to treatment populations were observed in ENHANCE (data not shown). Finally, multivariate logistic regression was used to test for the association between mortality and time to treatment, while simultaneously adjusting for multiple covariates. After adjustment for disease severity measures (APACHE II score and number of organ dysfunctions), the time to treatment association remained statistically significant (p ϭ .01) with an odds ratio of 0.782 (95% CI ϭ 0.643-0.951). The adjusted odds of death were 21.8% higher for patients treated later compared with those treated earlier.
When further adjusted for age, the association was not statistically significant (p ϭ .08). However, for patients 65 yrs of age or older, the increase in the predicted odds of death was 26.5% higher (p ϭ .02). In contrast, for patients younger than 65, patients treated later had an estimated 12.2% increase in the odds of death (p ϭ .38).
DISCUSSION
The PROWESS clinical trial demonstrated that DrotAA significantly reduced mortality in severe sepsis patients, with a moderate increased risk of bleeding (4) . To obtain additional efficacy and safety information concerning DrotAA among patients with severe sepsis, the global open-label trial in severe sepsis, EN-HANCE, was performed. Conducted at 361 sites, in 25 countries, with 2,378 patients, ENHANCE provides further support for the safety and efficacy of DrotAA observed in PROWESS. In addition, data indicate that earlier treatment with DrotAA may be associated with increased survival. (12) CI, confidence interval; DrotAA, drotrecogin alfa (activated); ICH, intracranial hemorrhage. a Rates were calculated based on patients who experienced at least one serious bleed event during the indicated periods. It was possible patients could experience more than one event. There were six patients who experienced an event in both the infusion and postinfusion periods. This is reflected in the 28-day period. Due to clearly demonstrated efficacy at an interim analysis, the PROWESS trial was stopped early (4) . Subsequently, the very success of PROWESS raised difficult issues concerning follow-up studies. Conducting a randomized, placebocontrolled trial, in the light of evidence from a successful trial, presents serious ethical issues for investigators. In addition, regulatory approval of DrotAA introduced a potential bias in conducting a placebo-controlled trial in severe sepsis. That is, availability of commercial product introduces the option of unblinding study patients who decline rapidly to offer them an approved therapy. As patients randomized to placebo must always be included in the placebo "intent-to-treat" group, postrandomization treatment of placebo patients with DrotAA may confound interpretation of the overall mortality rate for this group. Consequently, an open-label trial design was employed for ENHANCE. The use of early (phase II) and supplementary (phase IIIB/IV) trials to provide confirmatory evidence of safety and efficacy in support of a single randomized, placebo-controlled phase III study is consistent with recent recommendations (11) .
In presenting the ENHANCE data, a number of points are important to consider. Perhaps most important is the inherent weakness of a nonrandomized, open-label trial with no placebo control. However, PROWESS and ENHANCE patients demonstrated reasonable similarity with respect to a number of important demographic (age and gender), baseline clinical (morbidity and type of infection), and acute physiologic dysfunction/severity of illness variables (baseline organ dysfunction or use of ventilatory/vasopressor support). Since a primary objective of ENHANCE was to provide additional evidence for the mortality estimate in DrotAA-treated patients of PROWESS and not to further estimate the potential treatment effect against placebo, we believe that the ENHANCE results are supportive of the efficacy demonstrated in PROWESS. Despite the fact that the inclusion and exclusion criteria may represent a somewhat restricted sample of the entire population of patients with severe sepsis, the ENHANCE results support the conclusion that patients with these specific criteria would receive benefit from DrotAA treatment.
From a practical point of view, the potential impact of emerging therapies on ENHANCE needs to be considered. Although not having a placebo control may confound direct assessment of this, the ENHANCE cumulative mortality data suggest that there was no apparent decrease in mortality over the course of the trial. Furthermore, if new therapies were to have had an impact, they would be expected to have a similar impact on all severe sepsis clinical trials. In other recent placebo-controlled severe sepsis clinical trials, there has been no clear evidence of this type of effect (12, 13) . Although placebo mortality appeared to decrease over time in the Tifacogin (recombinant tissue factor pathway inhibitor) trial, a similar increase in mortality was observed in the Tifacogin arm, and neither the reduction in placebo mortality, nor the failure of the trial, was ascribed to the effect of new therapies (12) . In the platelet-activating factor-acetylhydrolase (PAF-AH) trial (13) , placebo mortality was lower than PAF-AH mortality (24% vs. 25%). The authors concluded the lower than anticipated placebo mortality might have been expected considering 75% of patients had only one or one organ dysfunctions (mortality rate in this subgroup was 22%). These dysfunctions may have included organ dysfunctions based on coagulopathy measures and/or the Glasgow Coma Scale score, which were not included in ENHANCE. Without these additional organ dysfunctions, 45% of ENHANCE patients had one or two organ dysfunctions with a mortality rate of 17% (data not shown). Furthermore, if these two additional organ dysfunction criteria for the PAF-AH trial were applied to the PROWESS placebo group (322 patients with one or two organ dysfunctions, data not shown), there would be an associated mortality rate of 22%, which is similar to the placebo group in the PAF-AH trial. Thus, there is no clear evidence for an impact of emerging therapies on the mortality observed in ENHANCE or other recently completed trials.
By comparison to PROWESS (4), ENHANCE was conducted at more than twice the number of sites (361 vs. 164) and countries (25 vs. 11) and had approximately three times the number of DrotAA-treated patients (2,378 vs. 850 ). In the ENHANCE trial, the majority of patients came from outside the United States, predominantly from Europe, whereas patients in PROWESS were predominantly from the United States. A primary objective of ENHANCE was to provide supportive efficacy evidence for the PROWESS trial. The 28-day all-cause mortality rate observed in ENHANCE (25.3%) was very close to the DrotAA treatment arm of PROWESS (4) (24.7%), and the 28-day pattern of survival was essentially identical. Considering that ENHANCE was performed in many more countries with inherent differences in standard of care, it is reassuring that the 28-day all-cause mortality of ENHANCE was so similar to the DrotAA treatment arm of PROWESS.
This may not be unexpected, given the similarity of the inclusion and exclusion criteria. However, differences were observed in baseline characteristics, notably the lower baseline APACHE II scores in ENHANCE compared with PROWESS, which contrasted with the greater levels of organ dysfunction evident in ENHANCE. This apparent contradiction may reflect the later treatment of patients in ENHANCE. Patients' APACHE II scores (worst value within 24 hrs of receiving DrotAA) may have been recorded for the study after their initial 24 hrs of resuscitation within the intensive care unit with some resulting correction of values used to calculate the score. The higher APS score in patients treated early suggests this as well (Table 4) . The APS score is a component of the APACHE II score that only collects basic physiology values. It will not recognize or "score" vasopressor use or mechanical ventilation, which may correct the physiology values during resuscitation. In addition, the apparent reversal of lower observed mortality rate, compared with PROWESS placebo, in the second and third APACHE II quartiles may also be a result of the later treatment of patients in ENHANCE. Indeed, EN-HANCE patients most similar to PROWESS patients (i.e., those treated earlier) were clearly more comparable to the PROWESS data (Tables 2 and 5 ). This observation is a reminder of the potential weakness in using APACHE II as a descriptor for individual patient severity of illness. This may be especially true in circumstances where the lead-time bias phenomenon may exist and where there are discrepancies with simpler descriptive assessments of illness severity, such as SOFA score and number of organ dysfunctions. Pertinent to this issue is the fact that more than half the patients in ENHANCE (64%) had APACHE II scores Ͻ25.
From a safety perspective, ENHANCE had a somewhat higher bleeding rate and a higher rate of ICH than reported for the DrotAA arm of PROWESS (4). However, fatal ICH events were the same during infusion and only moderately higher postinfusion and during the 28-day period. In PROWESS, the proportion of patients experiencing a serious bleeding event during the infusion period was higher for DrotAA patients compared with placebo patients. However, the proportion of patients experiencing a serious bleeding event during the postinfusion period was similar between the DrotAA and placebo groups (1.2% vs. 1.1%). Thus, the PROWESS data implied that bleeding risks associated with DrotAA were predominantly confined to the infusion period (4) . In ENHANCE, the proportion of patients experiencing a serious bleeding event was higher than that observed for DrotAA patients in the PROW-ESS trial, not only during the infusion period (3.6% vs. 2.4%) but also during the postinfusion period (3.2% vs. 1.2%), presumably when any DrotAA infusion effect would be gone. This observation may suggest that there was a higher background bleeding rate in ENHANCE. The larger numbers of surgical patients and higher hematologic and hepatic SOFA scores in ENHANCE may have also contributed to the observed increase in bleeding.
Although ENHANCE was an openlabel trial, compelling data with potentially important implications were observed. The time-to-treatment data were unique to the present study and suggested that a statistically significant association between mortality and duration of organ dysfunction (time to treatment) existed within the ENHANCE data. Specifically, earlier use of DrotAA was associated with a higher survival rate. Patients treated within 24 hrs of their first organ dysfunction had significantly lower observed mortality rate than patients treated after 24 hrs (22.9% vs. 27.4%, respectively). As might be expected, patients treated later had greater disease severity than those treated early. However, after controlling for multiple measures of disease severity, the differences persisted in a multivariate model. The lower observed mortality rate for patients treated earlier suggests that more effective use of DrotAA might be achieved by initiating therapy earlier. In this context, it is possible that patients treated earlier may recover earlier, which could potentially provide an overall resource savings. Although ENHANCE patients treated later had higher mortality rate than patients treated earlier, their mortality rate was still numerically lower than the PROWESS placebo group, suggesting that patients treated later may still receive benefit. The data also suggested that timing might matter more for older patients, perhaps due to more limited physiologic reserve. With respect to bleeding events, even though disease severity and mortality by disease severity were greater in patients treated later, no differences were observed between patients treated early or late. Similar results have been observed in previous disease severity subgroup analysis (14) .
CONCLUSIONS
The ENHANCE clinical trial provides further evidence of a favorable benefit-risk profile of drotrecogin alfa (activated) in the treatment of severe sepsis. Twenty-eight day all-cause mortality in ENHANCE was effectively the same as in PROWESS DrotAA-treated patients, and bleeding, although somewhat higher in ENHANCE, was still low and manageable. A significant time to treatment effect was also observed. Patients treated within the first 24 hrs exhibited lower mortality rate than patients treated after the first 24 hrs, regardless of disease severity. These data may suggest that more effective use of DrotAA could be achieved by initiating treatment earlier.
Future trials designed to better characterize the time to treatment effect should help provide important information for further development of treatment strategies in severe sepsis.
